Last Updated: September 24, 2026

Litigation Details for Lucent Technologies, Inc. v. Gateway, Inc. (S.D. Cal. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Lucent Technologies, Inc. v. Gateway, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Lucent Technologies, Inc. v. Gateway, Inc., 3:07-cv-02000: Litigation Summary and Patent Analysis

Last updated: August 12, 2026

Lucent Technologies’ case against Gateway was part of a broader patent campaign involving digital-audio compression technology used in software and personal computers. The dispute centered principally on U.S. Patent No. 5,341,457, which Lucent alleged covered technology incorporated into MP3 and related audio-encoding functionality. The litigation was filed in the U.S. District Court for the Southern District of California and became procedurally linked to Lucent’s parallel claims against Microsoft and Dell.

The case is best known for its connection to the $1.52 billion jury verdict against Microsoft. That verdict was later vacated in material respects by the Federal Circuit because the damages record did not support the royalty calculation. The Gateway docket did not produce an enduring damages judgment comparable to the original Microsoft verdict. The Federal Circuit’s decision remains the principal reported authority associated with the litigation. [1]

What was Lucent Technologies v. Gateway about?

Lucent alleged that Gateway’s products infringed patents relating to digital audio compression and decoding. The accused technology was associated with software and computer systems capable of handling MP3 audio files and other compressed audio formats.

Lucent’s theory was that Gateway, like Microsoft and Dell, distributed or sold products that practiced patented audio-processing techniques. The case was part of a larger enforcement strategy by Lucent and its successor interests against major computer and software companies.

The central patent was:

Patent Technology Relevance
U.S. Patent No. 5,341,457 Digital audio signal encoding and decoding Principal patent associated with the Lucent-Microsoft-Gateway litigation

The patent concerned methods for compressing digital audio data while preserving acceptable sound quality. The dispute did not concern a pharmaceutical product, biologic, medical device, or regulated therapeutic use.

What patents did Lucent assert against Gateway?

The reported appellate litigation principally focused on the '457 patent. Lucent asserted claims directed to audio-compression techniques that it argued were implemented by Microsoft software and incorporated into computers sold by Gateway and Dell.

The litigation record is frequently cited for two separate propositions:

  1. Patent infringement can be established through technical evidence showing that software performs claimed signal-processing steps.
  2. A reasonable royalty cannot be calculated solely by applying a large percentage to the entire market value of a product when the patented feature is only one component of that product.

The Federal Circuit treated the '457 patent as valid and enforceable for purposes of the infringement dispute then before it. The court’s principal intervention concerned damages and the evidentiary foundation for the royalty award. [1]

What was the procedural history of the Gateway case?

Filing and consolidation

Lucent filed the Gateway action in the Southern District of California under Case No. 3:07-cv-02000. The action followed Lucent’s earlier case against Microsoft, Case No. 3:06-cv-00684, and a related action against Dell.

The cases involved overlapping patent technology, accused products, technical experts, and damages theories. The district court managed the actions in a coordinated manner, although the Microsoft proceeding became the primary trial vehicle.

Jury verdict involving Microsoft

In 2007, a jury found Microsoft liable for infringement of the '457 patent and awarded Lucent approximately $1.52 billion. Lucent’s damages theory used a royalty rate applied to Microsoft’s sales of products that included the accused functionality.

The original verdict attracted attention because the asserted audio technology was embedded in widely distributed software rather than sold as a separately priced product. Gateway was commercially relevant because its computers incorporated or distributed products using the accused audio functionality.

District court post-trial proceedings

The district court later rejected the $1.52 billion damages award. It concluded that the damages calculation lacked adequate support and that the evidence did not establish the appropriate royalty base or royalty rate.

The district court’s analysis focused on whether the jury could reasonably use the entire market value of a product or software package as the royalty base when the patented audio feature represented only a small part of the accused product.

Federal Circuit appeal

The Federal Circuit issued its principal decision in 2009 in Lucent Technologies, Inc. v. Gateway, Inc., 580 F.3d 1301 (Fed. Cir. 2009). The court affirmed important aspects of the infringement and validity findings but vacated the damages award and remanded for further proceedings. [1]

The opinion is widely cited in patent damages litigation because it rejected unsupported use of the entire market value rule and required a stronger evidentiary connection between the patented feature and the royalty calculation.

What did the Federal Circuit decide?

The Federal Circuit’s decision had four major components.

Infringement evidence

The court held that the record could support a finding that the accused Microsoft functionality practiced the asserted claims. The dispute turned on the operation of the software and whether the relevant audio-processing steps were performed as claimed.

Patent validity

The court did not invalidate the '457 patent on the grounds presented in the appeal. The validity ruling preserved the patent’s legal significance during the period at issue, although the patent was an older patent with a limited remaining term.

Entire market value rule

The court held that the entire market value rule applies only when the patented feature drives demand for the entire accused product. The presence of an infringing feature in a larger software package or computer does not, by itself, justify using the full product price as the royalty base.

The court stated that the patentee must prove that the patented feature creates consumer demand for the entire product or that the parties would have negotiated a royalty based on the entire product value. [1]

Reasonable royalty

The Federal Circuit found that the $1.52 billion award was not adequately supported. The jury’s royalty calculation relied on a 2002 license agreement involving the same patent, but the court determined that the agreement did not provide a sufficient basis for the royalty applied to Microsoft’s much larger and different transaction.

The decision required a damages analysis tied to the economic value of the patented technology, the scope of the license, comparable transactions, and the hypothetical negotiation date.

How strong was Lucent’s patent position?

Lucent’s position was mixed.

Issue Assessment
Technical relevance Strong enough to support substantial litigation against major technology companies
Validity The '457 patent survived the principal validity challenge addressed by the Federal Circuit
Infringement Supported by the evidence in the Microsoft proceeding
Damages Weak under the original royalty methodology
Remaining patent life Limited because the patent issued in 1994
Commercial leverage High before the damages ruling, materially reduced after vacatur

The case illustrates the difference between proving infringement and proving commercially significant damages. Lucent achieved meaningful rulings on infringement and patent validity, but the damages theory could not support the original award.

The '457 patent issued on August 23, 1994. As a pre-1995 patent, its term was generally measured from issuance rather than the modern 20-year term from the earliest effective nonprovisional filing date. Its ordinary term therefore extended approximately 17 years from issuance, subject to any applicable patent-term adjustment or other statutory modification. The patent’s ordinary term would have expired around August 23, 2011.

That limited remaining term reduced the practical value of remand proceedings and weakened the prospect of a long-running exclusionary remedy.

What litigation risks did Gateway face?

Gateway’s primary exposure came from the possibility that its computers were treated as products incorporating or distributing software that practiced the asserted audio-processing claims.

The principal risks were:

  • A finding of direct or indirect infringement based on product distribution.
  • A reasonable royalty based on sales of accused computers or software.
  • Potential damages covering pre-suit and post-suit sales, subject to notice and limitations.
  • Litigation costs associated with technical discovery and expert testimony.
  • Coordinated rulings that could affect Gateway, Dell, and Microsoft simultaneously.

Gateway’s exposure was moderated by the limits on damages recognized by the Federal Circuit. A patent owner could not automatically claim a royalty on the full price of a computer merely because the computer included software capable of processing MP3 files.

The decision also reduced the value of broad damages theories based on the entire sales volume of a multifunction product.

Did Gateway settle the case?

The reported record associated with the case does not establish a publicly reported Gateway settlement comparable to a major standalone patent-license transaction. The commercially important development was the Federal Circuit’s treatment of the damages judgment and the remand proceedings associated with the coordinated litigation.

The Microsoft litigation later proceeded through additional post-remand activity. The original $1.52 billion verdict did not remain an enforceable final damages award after the district court and Federal Circuit decisions.

A party evaluating Gateway’s historical exposure should therefore distinguish between:

  1. The original jury verdict against Microsoft.
  2. The separate Gateway docket.
  3. The Federal Circuit’s legal holdings on infringement, validity, and damages.
  4. Any later docket-specific dismissal, settlement, or administrative termination recorded in the district-court docket.

What was the impact on patent damages law?

Lucent v. Gateway is a leading Federal Circuit authority on reasonable royalties and the entire market value rule.

The decision established several practical rules:

  • The royalty base must correspond to the economic value of the patented invention.
  • A large product price cannot be used merely because the product contains the accused feature.
  • Comparable licenses must be sufficiently comparable in scope, technology, timing, and commercial context.
  • A prior license involving the patent does not automatically establish a royalty rate for a different licensee or product.
  • Expert damages opinions require a reliable factual basis.

The case remains relevant in software, semiconductor, telecommunications, consumer-electronics, and platform litigation. It is particularly important when a patent covers a small software function embedded in a larger device or software package.

Is Lucent v. Gateway relevant to pharmaceutical patent litigation?

No. The case has no Orange Book, Paragraph IV, Hatch-Waxman, biosimilar, FDA exclusivity, formulation, method-of-use, or pharmaceutical-manufacturing component.

The following regulatory concepts are not applicable:

Pharmaceutical issue Relevance to Lucent v. Gateway
FDA approval None
Orange Book listing None
Paragraph IV certification None
New chemical entity exclusivity None
Hatch-Waxman litigation None
Biosimilar litigation None
Formulation patent None
Drug method-of-use patent None
Generic launch date None

The case is relevant to patent litigation strategy, claim construction, infringement proof, damages, and licensing analysis, but not to drug exclusivity or regulated-product market entry.

What does the case mean for technology licensing strategy?

The case places substantial limits on royalty demands for embedded technology.

A licensor seeking a royalty on a complete computer, software suite, or platform must show one of the following:

  • The patented feature drives demand for the entire product.
  • The feature materially determines product pricing.
  • Comparable licenses use the entire product as the royalty base.
  • The hypothetical negotiation would reasonably have produced that structure.

Licensors should define the licensed technology, identify the smallest saleable unit when appropriate, and use comparable agreements with similar commercial terms. Licensees should challenge royalty analyses that rely on unrelated licenses, different markets, different bargaining positions, or products with materially different functionality.

Key Takeaways

  • Lucent’s Gateway litigation concerned digital-audio compression technology, principally U.S. Patent No. 5,341,457.
  • The case was linked to Lucent’s broader litigation against Microsoft and Dell.
  • The original $1.52 billion verdict was against Microsoft, not a lasting standalone Gateway damages award.
  • The Federal Circuit’s 2009 decision, 580 F.3d 1301, is the principal reported authority.
  • The patent infringement and validity findings received substantial support, but the damages methodology failed.
  • The decision restricted use of the entire market value rule for embedded software features.
  • The '457 patent’s ordinary term ended around August 23, 2011, reducing the commercial value of extended proceedings.
  • The dispute has no FDA, Orange Book, Paragraph IV, biosimilar, or pharmaceutical exclusivity implications.

FAQs

What court handled Lucent Technologies v. Gateway?

The case was filed in the U.S. District Court for the Southern District of California under Case No. 3:07-cv-02000.

What technology did the Lucent patent cover?

The principal technology involved digital audio encoding and decoding used in compressed-audio applications, including MP3-related functionality.

Was Gateway ordered to pay $1.52 billion?

The widely reported $1.52 billion verdict was entered against Microsoft. It should not be treated as a final Gateway damages judgment.

Why is Lucent v. Gateway cited in patent damages cases?

The Federal Circuit used the case to limit unsupported application of the entire market value rule and to require reliable evidence for a reasonable royalty.

Did the patent still have meaningful exclusivity after the appeal?

Only limited exclusivity remained. The '457 patent issued in 1994 and had an ordinary pre-1995 patent term of approximately 17 years from issuance, placing its expected expiration around August 2011.

References

  1. Lucent Technologies, Inc. v. Gateway, Inc., 580 F.3d 1301 (Fed. Cir. 2009).

  2. U.S. Patent No. 5,341,457, “Method and apparatus for encoding and decoding a signal,” issued Aug. 23, 1994.

  3. U.S. District Court for the Southern District of California. (2007). Lucent Technologies, Inc. v. Gateway, Inc., No. 3:07-cv-02000. Court docket.

  4. U.S. District Court for the Southern District of California. (2006). Lucent Technologies, Inc. v. Microsoft Corp., No. 3:06-cv-00684. Court docket.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.